

## TRAC, MedGenome announce Cancer Immunotherapy solution

ANI | New Delhi [India]  
July 22, 2017 Last Updated at 06:42  
IST



### ALSO READ

'Trump's push for lower drug prices to benefit Indian pharma'

Mylan-Biocon's breast cancer biosimilar gets USFDA panel nod

CCI orders detailed probe against pharma major Roche

Can Biocon, Mylan drugs be used for early breast cancer: HC

Biocon, Mylan breast cancer drugs approved by DCGI: HC told

Ad

Instapage Landing Pages are the most powerful way to optimize your ad spend  
Instapage  
Customizable landing pages that give your brand the emphasis it deserves

[Toronto](#) Recombinant Antibody Centre (TRAC) from the University of Toronto, [Canada](#) agreed to license MedGenome's patented [cancer](#) immunotherapy solution OncoPept to develop biomarkers for their drug candidates against immune modulators to treat [cancer](#).

The licensing will form the basis of a larger partnership between the two organizations that can be leveraged to bring novel antibody drugs to the Indian market.

The announcement was made at the one day Symposium recently held at the Hilton Mumbai, which was attended by scientists from over 25 Pharmaceutical companies including Sun Pharma, [Biocon](#) and Glenmark. The Symposium was inaugurated by Jordan Reeves, the Canadian Consul General in [India](#).

[India](#) adds over one million new [cancer](#) cases every year with greater than 60% mortality due to lack of effective therapies. Highly effective antibody drugs take years before they become available in India, and when available, have limited market uptake because of the price barrier. For example, the cost of

treatment for the new [cancer](#) immunotherapy drugs can be as high as one crore rupees for a year of therapy.

This provides a great opportunity for the Indian pharma companies to take advantage from the partnership between MedGenome and TRAC to bring new [cancer](#) immunotherapy drugs to the Indian market at affordable prices and further enhance the effectiveness of therapy by using the OncoPept platform to identify patients who will benefit maximally from the treatment.

[Toronto](#) Recombinant Antibody Centre based in Donnanley Centre at the University of [Toronto](#) has developed a state-of-the-art phage display platform with validated screening technologies, and created a portfolio of over 200 antibodies focusing on [cancer](#) and [cancer](#) immunotherapy.

Sam Santhosh, Founder of MedGenome, said "TRAC has the best platform in the world for

producing novel biologics. We are proud to partner with them by providing our OncoPept solution which can also help Pharmaceutical companies select the right patients for their clinical trials."

MedGenome is a leader in genomics-based research and diagnostics capturing over 80% of NGS-based diagnostics market in [India](#). It has developed patented algorithms and pipelines to identify [cancer](#) vaccines to select tumors that will respond to [cancer](#) immunotherapy drugs, such as checkpoint inhibitors.

The partnership will strengthen TRAC's drug discovery and development pipeline by incorporating genomics data to advance understanding of diseases at a molecular level, thereby creating better drugs and biomarkers for personalized therapies.

"MedGenome's pipeline to dissect the tumor microenvironment at a molecular level will help in identifying new targets for which novel antibodies can be made," said Dr. Sachdev Sidhu, Professor at University of [Toronto](#).

He also added, "MedGenome's unique knowledge in analyzing diseases at a population level through its research arm in [India](#) provides an unprecedented opportunity to create drugs that can be more effective in certain population groups.

*(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)*